Galenica: Half-year sales rise 7.1%, with pharmacy revenue up 6.2%
In short
Galenica’s sales rose 7.1% to CHF 2,136.5 million in the first half of 2026. Pharmacy revenue increased 6.2% to CHF 756.9 million, excluding Coop Vitality. The Swiss consumer healthcare market grew 0.2%, with weaker demand for cold and pain medicines and growth from allergy products, vitamins and minerals.
What it means for suppliers
- Plan category volumes separately: demand fell for cold and pain medicines, while allergy products, vitamins and minerals supported market growth.
- Distinguish pharmacy revenue growth from OTC demand when planning supply: GLP-1 weight-loss medicines helped lift prescription sales.
- Account for a larger outlet network in distribution planning: Galenica now has 384 pharmacies, a net increase of three.
Key facts
| Retailer | Galenica |
|---|---|
| Announced | |
| Categories | Prescription medicines, Cold and pain medicines, Allergy products, Vitamins and minerals |
| Effective from | First half of 2026 |
| Source | galenica.com |
Not listed at Galenica yet?
Tell us what you sell. We will tell you how listing works and whether now is a good moment.